<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To enhance the oncolytic activity of <z:e sem="disease" ids="C0019348" disease_type="Disease or Syndrome" abbrv="">herpes simplex</z:e> viruses (HSVs) control of immune-suppression and immune-resistance by <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells is important </plain></SENT>
<SENT sid="1" pm="."><plain>Myeloid-derived suppressor cells (MDSCs), which interfere with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-suppressive environments, are inhibited by <z:chebi fb="0" ids="175901">gemcitabine</z:chebi> (GEM) treatment </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the oncolytic activity and systemic antitumor immunity induced by oncolytic HSVs in combination with GEM treatment </plain></SENT>
<SENT sid="3" pm="."><plain>A mouse model with subcutaneous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> on both sides of the lateral flanks was used </plain></SENT>
<SENT sid="4" pm="."><plain>A highly attenuated HSV type 1, strain HF10, was inoculated into one side of each <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> three times following intraperitoneal injection of GEM </plain></SENT>
<SENT sid="5" pm="."><plain>Histopathological changes and IFN-Î³ secretion of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and leukocytes in the spleen were analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>These treatments were repeated to enhance oncolytic activity </plain></SENT>
<SENT sid="7" pm="."><plain>HF10 inoculation reduced <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> only on the HF10-treated side </plain></SENT>
<SENT sid="8" pm="."><plain>HF10 inoculation following GEM treatment resulted in greater reduction of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> on the HF10-treated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>; furthermore, reduction of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> on the contralateral untreated side was also observed </plain></SENT>
<SENT sid="9" pm="."><plain><z:mp ids='MP_0001651'>Necrosis</z:mp> of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> was observed in areas where HSV-infected cells were detected </plain></SENT>
<SENT sid="10" pm="."><plain>F4/80(+) macrophages around the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> were eliminated, and CD4(+) T and CD8(+) T cells increased in the spleen </plain></SENT>
<SENT sid="11" pm="."><plain>A single injection of GEM decreased CD11b(+) /Gr-1(+) MDSCs while retaining CD4(+) T cells and CD8(+) T cells </plain></SENT>
<SENT sid="12" pm="."><plain>Repetition of this treatment regimen resulted in even greater reduction of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> on both sides and complete rejection in some of the mice </plain></SENT>
<SENT sid="13" pm="."><plain>Intratumoral injection of oncolytic HSVs following GEM injection reduced MDSCs </plain></SENT>
<SENT sid="14" pm="."><plain>Repeated treatment with oncolytic HSVs following GEM resulted in enhanced oncolytic activity </plain></SENT>
</text></document>